Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jan 1;83(1):2-4.
doi: 10.1016/j.biopsych.2017.10.026.

Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions

Panos Zanos  1 , Todd D Gould  2
Affiliations
Comment

Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions

Panos Zanos et al. Biol Psychiatry. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

T.D.G. has received consulting fees from Janssen Pharmaceuticals, and research funding from Janssen Pharmaceuticals and Roche Pharmaceuticals during the preceding three years. P.Z., and T.D.G. are listed as co-authors in patent applications related to the pharmacology and use of (2S,6S)- and (2R,6R)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorder.

Comment on

References

    1. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry. 2016;80:424–431. - PubMed
    1. Zhang JC, Li SX, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141. - PubMed
    1. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632. - PMC - PubMed
    1. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486. - PMC - PubMed
    1. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J-i, Hashimoto K, et al. Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. Journal of Pharmacology and Experimental Therapeutics. 2017;361:9–16. - PubMed

Publication types